Summary: Experts discuss a breadth of analytical methodologies, fill & finish approaches and manufacturing designs to accelerate CAR-T therapies to commercial readiness phase in this on-demand webinar.

Summary: Both cell therapy innovators and manufacturing organizations are employing novel technologies and methodologies to adapt to an accelerated and evolving clinical landscape

Summary: Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors.

Summary: In this interview, Catalent expert Judith Jones discusses the challenges associated with advancing a repositioned drug and how to overcome them to achieve strategic success.

Summary: This roundtable is a must-watch for early and late-stage cell therapy innovator companies who are considering a manufacturing partnership.

Summary: In this webinar, experts discuss new cell line development methodologies and how the use of novel technologies can enable simplified process intensification for cell culture harvest and downstream processes.

Summary: CAR-T cell therapies require expertise in process development to successfully scale-up manufacturing. Working with an integrated partner like Catalent gives you the ability to manufacture at clinical and commercial scale efficiently and effectively for both autologous and allogeneic cell therapies.

Summary: Catalent has made significant investments in the cell and gene therapy space with strategic acquisitions and commitment to grow and innovate.

Summary: Catalent has made significant investments in capacity expansions to meet the growing demand of our customers.

Summary: The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines.